Drug trial aims to unlock heart transplants for High-Risk patients
NCT ID NCT05300451
Summary
This study is testing if a drug called daratumumab can lower high levels of harmful antibodies in people waiting for a heart transplant. High antibodies make it very hard to find a compatible donor heart. The goal is to see if this treatment can 'desensitize' patients, making more donor hearts a safe match and helping them get a transplant sooner.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.